Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 15, Issue 9, Pages 1359-1370Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2015.1071350
Keywords
angiogenesis; gastric cancer; ramucirumab; review
Funding
- Italian Association for Cancer Research [AIRC-MFAG 14282]
- International Association for Lung Cancer (IASLC)
Ask authors/readers for more resources
Introduction: Angiogenesis plays a pivotal role in the development and progression of tumors and it represents a crucial target for therapeutic strategies. Until now, regulatory agencies approved antiangiogenic agents targeting the VEGF and multi-target agents carrying antiangiogenic and anti-proliferative effects. They often provide only a modest survival benefit and their role in clinical practice is debated. The limited efficacy may be partially explained by the complexity of the molecular background of angiogenic processes, composed of several pathways interacting with both tumor cells and the microenvironment. Areas covered: Ramucirunnab is a fully human monoclonal antibody selectively binding and inhibiting the VEGF receptor 2 (VEGFR-2), a crucial molecule involved in angiogenesis. A series of Phase I-II trials conducted in a wide spectrum of malignancies reported promising antitumor activity. In 2014, data from large Phase III clinical trials in gastrointestinal, lung and breast malignancies were released. Expert opinion: Considering the evidences of efficacy emerging from the available Phase III trials, the antiangiogenic approach emerged as a promising strategy particularly for the treatment of gastric cancer. Nevertheless, the identification and validation of potentially predictive biomarkers are necessary to improve the selection of patients and the globally awaited clinical benefit.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available